Introduction
Very low birth weight (VLBW) infants treated in the neonatal intensive care unit (NICU) are at risk for late-onset sepsis. A multi-center report showed that Candida albicans is the third most common organism isolated in the first episode of late-onset sepsis in VLBW infants. 1 In this birth weight group, fungal infections are twice as likely to cause death compared to other infections. Furthermore, infants diagnosed with candidiasis had increased neurodevelopmental impairment at 18-22 months compared to those without this diagnosis. 1, 2 Immature immune system, long-term need for central vascular access, the use of broad-spectrum antibiotics, increased permeability of skin and mucosal barriers, and the need for respiratory support are among the risk factors for invasive candidiasis. [3] [4] [5] [6] A recent multivariate analysis controlling for birth weight identified catheter-days, prior bacterial blood stream infection, and gastrointestinal tract pathology as the significant risk factors for invasive candida infection. 6 Fluconazole prophylaxis has been shown to reduce candida colonization and/or infection in VLBW infants. 4, [7] [8] [9] [10] [11] In 2001, Kaufman et al. 4 reported results of a small randomized clinical trial showing that the prophylactic intravenous administration of fluconazole prevented fungal colonization and invasive fungal disease in extremely low birth weight (ELBW) infants without adverse effects. In 2005 and 2006, three studies reported data after implementing different fluconazole prophylaxis schedules and showed favorable results. [10] [11] [12] To our knowledge, the potential hepatoxicity related to fluconazole prophylaxis in ELBW infants has been only partially addressed in the literature. Previous reports included evaluation of the levels of transaminases as a marker for hepatotoxicity. No significant increase in serum transaminase levels was observed with fluconazole prophylaxis in these studies. 4,7,8,10 -13 In addition to the increased risk for invasive candidiasis, ELBW are at risk for cholestasis. Sepsis, parenteral nutrition, and delayed enteral feedings are among the factors contributing to the development of cholestasis in this population. 14 The introduction of a potentially hepatotoxic drug could be an additional risk for cholestasis in these infants.
In March 2002, we adopted the prophylaxis regimen used by Kaufman et al. 4 as part of our management of infants p1000 g. The lack of a large multi-center clinical trial to support this practice and concern for the safety of the routine use of fluconazole prompted us to look closely at the laboratory data of our ELBW infants after implementing the prophylaxis protocol. The purpose of this study is to review the outcome of infants receiving fluconazole prophylaxis and compare them to a historical group from the pre-fluconazole prophylaxis era. Compared to other reports, which focused on liver enzymes, we sought to evaluate all available laboratory results concerning liver functions in this population in the two eras.
Materials and methods
This is a retrospective, nonrandomized study with historical controls for infants admitted to our 35-bed, level III NICU at Cooper University Hospital in Camden, New Jersey. Infants with birth weight p1000 g born between January 1998 and September 2005 were eligible for this study. The Institutional Review Committee at Cooper University Hospital approved this study.
Pre-prophylaxis era (PPE)
Infants with birth weight p1000 g and born between January 1998 and February 2002 served as historical controls.
Prophylaxis era (PE)
Infants with birth weight p1000 g and born between March 2002 and September 2005 received 6 weeks of intravenous fluconazole prophylaxis as described by Kaufman et al. 4 The infants received 3 mg/kg/dose, every 72 h Â 2 weeks; every 48 h Â 2 weeks and daily Â 2 weeks. 4, 11 Fluconazole prophylaxis was discontinued earlier if the infant no longer required intravascular access.
Infants with birth weight p1000 g and born in the period from January 1998 to September 2005 were identified from a relational database, Neonatal Information System III (NIS-Medical Data Systems, Wayne, PA, USA). The following data were collected: date of birth, gestational age, birth weight, sex, race, antenatal corticosteroids, prenatal antibiotics, rupture of membranes (ROM) more than 24 h before delivery, type of delivery, apgar scores, use of ampicillin and gentamicin, use of third-generation cephalosporins, use of vancomycin, duration of antibiotic therapy, duration of umbilical catheter, presence and duration of central venous catheters, positive blood cultures, duration of parenteral nutrition, and the presence and duration of mechanical ventilation. Other data related to complications of prematurity including bronchopulmonary dysplasia (BPD), necrotizing entrocolitis (NEC), patent ductus arteriosus (PDA) requiring ligation, intraventricular hemorrhage (IVH), and retinopathy of prematurity (ROP) were collected. Invasive fungal infection was defined by a positive culture of blood or cerebrospinal fluid.
The baseline neonatal and maternal characteristics, complications of prematurity, the risks for candida sepsis, rate of invasive candidiasis, risk factors for conjugated hyperbilirubinemia, and liver function tests (aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, total and direct bilirubin) were compared in infants from PPE and PE.
Statistics were performed using Sigma Stat 3.1 for Windows statistical package (Systat Software, Inc., Point Richmond, CA, USA). The comparisons between groups were performed using Student's t-test and Mann-Whitney U-test for continuous data and w 2 or Fisher's exact test for categorical data. The levels of total and direct bilirubin, liver enzymes, and alkaline phosphatase were compared at various time points between the two groups by repeated measures analysis of variance. The difference was considered significant for P<0.05.
Results
There were 277 infants with birth weight of p1000 g admitted between January 1998 and September 2005: 137 infants born during PPE and 140 infants born during PE. Except for a significant number of mothers receiving prenatal steroids and infants receiving surfactant treatment in the PE, there were no differences in the demographics and other baseline clinical characteristics between the two groups ( Table 1) . Table 2 shows the risk factors for invasive candidiasis in the two groups. Infants in PE received antibiotics therapy and mechanical ventilation for significantly longer period than infants in the PPE. Also, more infants in PE received vancomycin compared to PPE. Invasive candida infection developed in nine out of 137 infants during PPE (6.6%), and none out of 140 infants born during PE (0%) (P ¼ 0.006). The overall mortality rate was significantly higher in infants born during PPE (39.4%) compared to infants born during PE (25.7%) (P ¼ 0.02). There was no significant difference in major morbidities associated with prematurity in these two groups (Table 3) . Table 1 Demographics and baseline clinical characteristics of infants born during pre-prophylaxis era (PPE) and prophylaxis era (PE) All invasive fungal infections in the PPE were caused by Candida albicans and were treated with amphotericin B. All nine infants had positive blood cultures and one infant had a positive urine culture. Three infants had cerebrospinal fluid drawn and all were negative for candida. The median age of diagnosing invasive candidiasis was 17 days (range 12-32 days). Six out of nine infants who had invasive candidiasis died (case fatality rate 66.6%) and the cause of death for each of these infants was reported as overwhelming candida sepsis. The median age at death was 29 days (range 25-46 days). Infants who developed invasive candidiasis during PPE significantly differed from those who did not have invasive candidiasis with regard to gestational age, birth weight, days of mechanical ventilation, postnatal steroids, history of bacterial infection, total days of antibiotics, treatment with vancomycin, treatment with a third-generation cephalosporin, and diagnosis of NEC during the hospitalization. The median gestational age and birth weight of infants who developed invasive candidiasis were 24 weeks (range, 23-29 weeks) and 587 g (range, 520-850 g), respectively. Eight out of nine infants who developed invasive candidiasis had a birth weight of less than 750 g. During PPE, the incidence of invasive candidiasis was 11.1% (8/72) in infants with birth weight p750 g compared to 1.5% (1/65) in infants with birth weight of 751-1000 g (Table 4 ).
There was no significant difference in risk factors for conjugated hyperbilirubinemia (CH) between the two groups ( Table 5) . Conjugated hyperbilirubinemia (direct bilirubin >2.0 mg/dL) was diagnosed in 42.9% of the infants in PE compared to 8.8% in PPE (P<0.001). The number of infants with direct bilirubin of >5 and >10 mg/dL were also significantly higher in infants born during PE. The duration of CH was prolonged in infants born during the fluconazole prophylaxis and more infants were treated with ursodeoxycholic acid during PE. However, the number of infants with a diagnosis of CH at discharge was similar during the two eras ( Table 6 ).
The level of direct bilirubin was significantly higher at weeks 3, 4, 6, and 8 in infants born during PE compared to PPE (all P<0.05) (Figure 1 ). The level of total bilirubin was also higher at similar time points in infants during PE. There was no significant difference in the levels of AST, ALT, and alkaline phosphatase between the two groups (data not shown). There was also no significant difference in the number of infants with AST and ALT more than 250 IU/L during PPE and PE (Table 6 ).
Discussion
We report in this study that a significant increase in conjugated hyperbilirubinemia in ELBW infants was observed after adopting a flucanazole prophylaxis regimen. Fluconazole prophylaxis was, however, effective in reducing the incidence of invasive candidiasis in our NICU. The enthusiasm towards using fluconazole prophylaxis in our NICU started after Kaufman et al. 4 reported a reduction in candida infection in a small randomized controlled trial. To date, a large multi-center randomized controlled trial to evaluate this practice has not yet been conducted. Nevertheless, there have been reports from centers which adopted different prophylaxis regimens and showed comparable results with regard to effectiveness. [10] [11] [12] [13] Hepatotoxicity, however, remains a major concern among clinicians and skepticism regarding the use of fluconazole prophylaxis as part of the management of ELBW infants has resulted in at least two editorials from experienced neonatologists and infectious disease specialists. 15, 16 In addition to the lack of knowledge regarding long-term outcomes, the experts PPE, pre-prophylaxis era; PE, prophylaxis era; TPN, total parenteral nutrition. are also concerned about the uncertainty regarding the potential toxicities and emergence of resistant pathogens. 9, 15, 16 So far, most of the studies on fluconazole prophylaxis in preterm infants were focused on elevation of liver enzymes as a marker for hepatotoxicity. Our data, as well as those of reported studies, show that there was no significant increase in liver enzymes with fluconazole prophylaxis. 4,7,8,10 -13 Our results raise the possibility that by solely monitoring transaminases, we may be 
ALT, alanine aminotransferase; AST, aspartate aminotransferase; PE, pre-prophylaxis era; PE, prophylaxis era. The levels of direct bilirubin over time in infants born during PPE and PE. The level of direct bilirubin was significantly higher on weeks 3, 4, 6, and 8 in infants born during PE (*P<0.05). The boundary of the box indicates the 25th and 75th percentiles, the line within the box marks the median value, and the error bars indicate the 5th and 95th percentile.
underestimating the hepatotoxicity of fluconazole in ELBW infants. To our knowledge, this is the first study to report increased incidence of CH with fluconazole prophylaxis in preterm infants. Fluconazole prophylaxis was not only associated with increase incidence of CH but also the magnitude and duration of cholestasis in ELBW infants. There was no significant difference in the incidence of CH at the time of discharge between the two eras. Uko et al. 13 reported decreased cholestasis with targeted short-term fluconazole prophylaxis in LBW infants. However, they definined cholestasis as direct bilirubin >5 mg/dL and the duration of fluconazole prophylaxis was shorter in their study.
Balancing the risks and benefits of using fluconazole prophylaxis in ELBW infants needs to be addressed in the literature. Before fluconazole prophylaxis, the incidence of invasive candida infection in infants p1000 g in our NICU was 6.6% with a case fatality rate of 66.6%. On the other hand, there is a wide range in the reported incidences (0.65-20%) of systemic fungal infection in ELBW infants even in the most recent literature. 4,6,7,10 -12,16-18 Infection control practices, policies around limits of viability, difference in the definition of invasive candidiasis, and the status of the institution (inborn centers versus referral centers) may account for this wide range in incidences among centers. Furthermore, mortality from fungal infection falls in the range from 11.4 to 44%. 1, 4, 7, 8, 11, 12, 17, 19 The number needed-to-treat (NNT) to prevent one invasive candida infection ranges from 5 to 200 ELBW infants, while the NNT to prevent one death ranges from 20 to 560 ELBW infants. 16 Given the potential toxicity, the risk of a universal fluconazole prophylaxis may outweigh its benefits in the units that already have low incidence of invasive canidiasis. More recently, Kaufman et al. reported results from another small trial comparing their original dosing regimen to a twice weekly dosing regimen. The twice weekly dosing of fluconazole decreased invasive candida infection with the additional advantage of less cost, less drug exposure in the infants and potentially less emergence of drug resistance. 4, 7 In our cohort, the incidence of invasive candidiasis was 11.1% (8/72) in infants with birth weight p750 g and only 1.5% (1/65) in infants with birth weight of 751-1000 g. Considering potential hepatotoxicity, targeting fluconazole prophylaxis in smaller infants (p750 g) may result in a lower NNT to prevent one invasive candidal infection with a higher benefit versus risk ratio.
Despite the limitation of our retrospective study, we conclude that a fluconazole prophylaxis regimen was effective in preventing invasive fungal infections in ELBW infants but was associated with increased conjugated hyperbilirubinemia in our NICU. It was previously noted that data like ours are of great value for the management of ELBW infants in a non-research setting. 11 However, neonatologists managing these infants should remain aware that the benefit of implementing this practice could vary from one NICU to another. Furthermore, it has yet to be determined whether different dosing regimens as suggested by others, or targeting smaller infants, would prove safe and beneficial.
